{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:07:38Z","timestamp":1792534058152,"version":"4.5.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-01985-7","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T12:55:07Z","timestamp":1740401707000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Multifaceted role of heparin in oncology: from anticoagulation to anticancer mechanisms and clinical implications"],"prefix":"10.1007","volume":"16","author":[{"given":"Niranjan","family":"Koirala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina","family":"Poudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit Kumar","family":"Shrivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romit Kumar","family":"Subba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamata","family":"Panthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samrat","family":"Paudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab M.","family":"Almarhoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javad","family":"Sharifi-Rad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Calina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"issue":"3","key":"1985_CR1","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.athoracsur.2019.03.104","volume":"108","author":"CS Ong","year":"2019","unstructured":"Ong CS, Marcum JA, Zehr KJ, Cameron DE. A century of heparin. Ann Thorac Surg. 2019;108(3):955\u20138. https:\/\/doi.org\/10.1016\/j.athoracsur.2019.03.104.","journal-title":"Ann Thorac Surg"},{"key":"1985_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/life13091888","author":"V Russo","year":"2023","unstructured":"Russo V, Falco L, Tessitore V, Mauriello A, Catapano D, Napolitano N, Tariq M, Caturano A, Ciccarelli G, D\u2019Andrea A, Giordano A. Anti-inflammatory and anticancer effects of anticoagulant therapy in patients with malignancy. Life. 2023. https:\/\/doi.org\/10.3390\/life13091888.","journal-title":"Life"},{"issue":"10","key":"1985_CR3","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.3390\/ph16101385","volume":"16","author":"I Pagani","year":"2023","unstructured":"Pagani I, Ottoboni L, Panina-Bordignon P, Martino G, Poli G, Taylor S, Turnbull JE, Yates E, Vicenzi E. Heparin precursors with reduced anticoagulant properties retain antiviral and protective effects that potentiate the efficacy of sofosbuvir against zika virus infection in human neural progenitor cells. Pharmaceuticals. 2023;16(10):1385.","journal-title":"Pharmaceuticals"},{"issue":"4","key":"1985_CR4","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3390\/ph16040584","volume":"16","author":"JK Shute","year":"2023","unstructured":"Shute JK. Heparin, low molecular weight heparin, and non-anticoagulant derivatives for the treatment of inflammatory lung disease. Pharmaceuticals. 2023;16(4):584.","journal-title":"Pharmaceuticals"},{"issue":"3","key":"1985_CR5","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1097\/ta.0000000000003257","volume":"91","author":"KD Checchi","year":"2021","unstructured":"Checchi KD, Costantini TW, Badiee J, Berndtson AE, Calvo RY, Rooney AS, Wessels LE, Prieto JM, Sise CB, Sise MJ, Martin MJ, Bansal V. A tale of two centers: Is low-molecular-weight heparin really superior for prevention of posttraumatic venous thromboembolism? J Trauma Acute Care Surg. 2021;91(3):537\u201341. https:\/\/doi.org\/10.1097\/ta.0000000000003257.","journal-title":"J Trauma Acute Care Surg"},{"key":"1985_CR6","doi-asserted-by":"publisher","first-page":"1247253","DOI":"10.3389\/fphar.2023.1247253","volume":"14","author":"L Liu","year":"2023","unstructured":"Liu L, Zheng H, Chen S, Wang S, Yang M. Heparin-induced thrombocytopenia associated with low-molecular-weight heparin: clinical feature analysis of cases and pharmacovigilance assessment of the FAERS database. Front Pharmacol. 2023;14:1247253. https:\/\/doi.org\/10.3389\/fphar.2023.1247253.","journal-title":"Front Pharmacol"},{"issue":"8","key":"1985_CR7","doi-asserted-by":"publisher","first-page":"e007080","DOI":"10.1136\/jitc-2023-007080","volume":"11","author":"Y Quan","year":"2023","unstructured":"Quan Y, He J, Zou Q, Zhang L, Sun Q, Huang H, Li W, Xie K, Wei F. Low molecular weight heparin synergistically enhances the efficacy of adoptive and anti-PD-1-based immunotherapy by increasing lymphocyte infiltration in colorectal cancer. J Immunother Cancer. 2023;11(8):e007080. https:\/\/doi.org\/10.1136\/jitc-2023-007080.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"1985_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.critrevonc.2006.07.007","volume":"61","author":"TMH Niers","year":"2007","unstructured":"Niers TMH, Klerk CPW, DiNisio M, Van Noorden CJF, B\u00fcller HR, Reitsma PH, Richel DJ. Mechanisms of heparin induced anti-cancer activity in experimental cancer models. Crit Rev Oncol Hematol. 2007;61(3):195\u2013207. https:\/\/doi.org\/10.1016\/j.critrevonc.2006.07.007.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1985_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-3-642-23056-1_2","volume-title":"Heparin\u2014a century of progress","author":"P Carlsson","year":"2012","unstructured":"Carlsson P, Kjell\u00e9n L. Heparin biosynthesis. In: Lever R, Mulloy B, Page CP, editors. Heparin\u2014a century of progress. Berlin: Springer; 2012. p. 23\u201341."},{"key":"1985_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/978-3-642-23056-1_5","volume":"207","author":"B Mulloy","year":"2012","unstructured":"Mulloy B. Structure and physicochemical characterisation of heparin. Handb Exp Pharmacol. 2012;207:77\u201398. https:\/\/doi.org\/10.1007\/978-3-642-23056-1_5.","journal-title":"Handb Exp Pharmacol"},{"issue":"19","key":"1985_CR11","doi-asserted-by":"publisher","first-page":"6687","DOI":"10.1016\/S0021-9258(17)37973-5","volume":"253","author":"HC Robinson","year":"1978","unstructured":"Robinson HC, Horner AA, H\u00f6\u00f6k M, Ogren S, Lindahl U. A proteoglycan form of heparin and its degradation to single-chain molecules. J Biol Chem. 1978;253(19):6687\u201393.","journal-title":"J Biol Chem"},{"issue":"2","key":"1985_CR12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.coph.2011.12.002","volume":"12","author":"RJ Linhardt","year":"2012","unstructured":"Linhardt RJ, Liu J. Synthetic heparin. Curr Opin Pharmacol. 2012;12(2):217\u20139. https:\/\/doi.org\/10.1016\/j.coph.2011.12.002.","journal-title":"Curr Opin Pharmacol"},{"key":"1985_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/0008-6215(87)80268-9","volume":"167","author":"M Petitou","year":"1987","unstructured":"Petitou M, Duchaussoy P, Lederman I, Choay J, Jacquinet JC, Sina\u00ff P, Torri G. Synthesis of heparin fragments: a methyl alpha-pentaoside with high affinity for antithrombin III. Carbohyd Res. 1987;167:67\u201375. https:\/\/doi.org\/10.1016\/0008-6215(87)80268-9.","journal-title":"Carbohyd Res"},{"issue":"Suppl 3","key":"1985_CR14","first-page":"5","volume":"25","author":"RJ Linhardt","year":"1999","unstructured":"Linhardt RJ, Gunay NS. Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost. 1999;25(Suppl 3):5\u201316.","journal-title":"Semin Thromb Hemost"},{"issue":"2 Suppl","key":"1985_CR15","doi-asserted-by":"publisher","first-page":"e24S","DOI":"10.1378\/chest.11-2291","volume":"141","author":"DA Garcia","year":"2012","unstructured":"Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e24S-e43S. https:\/\/doi.org\/10.1378\/chest.11-2291.","journal-title":"Chest"},{"issue":"5","key":"1985_CR16","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1160\/th08-01-0032","volume":"99","author":"E Gray","year":"2008","unstructured":"Gray E, Mulloy B, Barrowcliffe TW. Heparin and low-molecular-weight heparin. Thromb Haemost. 2008;99(5):807\u201318. https:\/\/doi.org\/10.1160\/th08-01-0032.","journal-title":"Thromb Haemost"},{"issue":"7","key":"1985_CR17","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1182\/blood-2008-02-078014","volume":"112","author":"JG Kelton","year":"2008","unstructured":"Kelton JG, Warkentin TE. Heparin-induced thrombocytopenia: a historical perspective. Blood. 2008;112(7):2607\u201316. https:\/\/doi.org\/10.1182\/blood-2008-02-078014.","journal-title":"Blood"},{"issue":"3","key":"1985_CR18","doi-asserted-by":"publisher","first-page":"188s","DOI":"10.1378\/chest.126.3_suppl.188S","volume":"126","author":"J Hirsh","year":"2004","unstructured":"Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126(3):188s\u2013203s. https:\/\/doi.org\/10.1378\/chest.126.3_suppl.188S.","journal-title":"Chest"},{"issue":"4","key":"1985_CR19","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1080\/10245330500093492","volume":"10","author":"KH Kuo","year":"2005","unstructured":"Kuo KH, Kovacs MJ. Fondaparinux: a potential new therapy for HIT. Hematology. 2005;10(4):271\u20135. https:\/\/doi.org\/10.1080\/10245330500093492.","journal-title":"Hematology"},{"issue":"9","key":"1985_CR20","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s13233-016-4111-8","volume":"24","author":"HH Hwang","year":"2016","unstructured":"Hwang HH, Lee DY. Antiangiogenic actions of heparin derivatives for cancer therapy. Macromol Res. 2016;24(9):767\u201372. https:\/\/doi.org\/10.1007\/s13233-016-4111-8.","journal-title":"Macromol Res"},{"key":"1985_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910524","author":"N Banik","year":"2021","unstructured":"Banik N, Yang SB, Kang TB, Lim JH, Park J. Heparin and its derivatives: challenges and advances in therapeutic biomolecules. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms221910524.","journal-title":"Int J Mol Sci"},{"key":"1985_CR22","doi-asserted-by":"publisher","first-page":"111561","DOI":"10.1016\/j.biopha.2021.111561","volume":"139","author":"M Qiu","year":"2021","unstructured":"Qiu M, Huang S, Luo C, Wu Z, Liang B, Huang H, Ci Z, Zhang D, Han L, Lin J. Pharmacological and clinical application of heparin progress: an essential drug for modern medicine. Biomed Pharmacother. 2021;139:111561. https:\/\/doi.org\/10.1016\/j.biopha.2021.111561.","journal-title":"Biomed Pharmacother"},{"key":"1985_CR23","doi-asserted-by":"publisher","first-page":"107602962110522","DOI":"10.1177\/10760296211052293","volume":"27","author":"A Al-Hakim","year":"2021","unstructured":"Al-Hakim A. General considerations for diversifying heparin drug products by improving the current heparin manufacturing process and reintroducing bovine sourced heparin to the US market. Clin Appl Thromb Hemost. 2021;27:10760296211052292. https:\/\/doi.org\/10.1177\/10760296211052293.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"6","key":"1985_CR24","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1177\/1076029616643822","volume":"22","author":"K St Ange","year":"2016","unstructured":"St Ange K, Onishi A, Fu L, Sun X, Lin L, Mori D, Zhang F, Dordick JS, Fareed J. Analysis of heparins derived from bovine tissues and comparison to porcine intestinal heparins. Clin Appl Thromb Hemost. 2016;22(6):520\u20137.","journal-title":"Clin Appl Thromb Hemost"},{"key":"1985_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1055\/s-2007-996063","volume":"01","author":"P Bianchini","year":"1997","unstructured":"Bianchini P, Liverani L, Mascellani G, Parma B. Heterogeneity of unfractionated heparins studied in connection with species, source, and production processes. Semin thromb hemost. 1997;01:3\u201310.","journal-title":"Semin thromb hemost"},{"issue":"1","key":"1985_CR26","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0021-9258(18)72576-3","volume":"144","author":"L Jaques","year":"1942","unstructured":"Jaques L, Waters E, Charles AJ. A comparison of the heparins of various mammalian species. J Biol Chem. 1942;144(1):229\u201335.","journal-title":"J Biol Chem"},{"issue":"4","key":"1985_CR27","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.cca.2003.10.009","volume":"136","author":"M Warda","year":"2003","unstructured":"Warda M, Gouda EM, Toida T, Chi L, Linhardt RJ. Isolation and characterization of raw heparin from dromedary intestine: evaluation of a new source of pharmaceutical heparin. Comparat Biochem Physiol Toxicol Pharmacol. 2003;136(4):357\u201365. https:\/\/doi.org\/10.1016\/j.cca.2003.10.009.","journal-title":"Comparat Biochem Physiol Toxicol Pharmacol"},{"issue":"1","key":"1985_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/s1096-4959(02)00250-6","volume":"134","author":"M Warda","year":"2003","unstructured":"Warda M, Mao W, Toida T, Linhardt RJ. Turkey intestine as a commercial source of heparin? Comparative structural studies of intestinal avian and mammalian glycosaminoglycans. Comp Biochem Physiol B: Biochem Mol Biol. 2003;134(1):189\u201397. https:\/\/doi.org\/10.1016\/s1096-4959(02)00250-6.","journal-title":"Comp Biochem Physiol B: Biochem Mol Biol"},{"issue":"1","key":"1985_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1055\/s-2007-996063","volume":"23","author":"P Bianchini","year":"1997","unstructured":"Bianchini P, Liverani L, Mascellani G, Parma B. Heterogeneity of unfractionated heparins studied in connection with species, source, and production processes. Semin Thromb Hemost. 1997;23(1):3\u201310. https:\/\/doi.org\/10.1055\/s-2007-996063.","journal-title":"Semin Thromb Hemost"},{"issue":"6","key":"1985_CR30","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.3390\/molecules22061025","volume":"22","author":"J-Y van der Meer","year":"2017","unstructured":"van der Meer J-Y, Kellenbach E, Van den Bos LJJM. From farm to pharma: an overview of industrial heparin manufacturing methods. Molecules. 2017;22(6):1025.","journal-title":"Molecules"},{"issue":"6","key":"1985_CR31","doi-asserted-by":"publisher","first-page":"e409","DOI":"10.1016\/j.thromres.2010.07.004","volume":"126","author":"R Flengsrud","year":"2010","unstructured":"Flengsrud R, Larsen ML, \u00d8degaard OR. Purification, characterization and in vivo studies of salmon heparin. Thromb Res. 2010;126(6):e409-417. https:\/\/doi.org\/10.1016\/j.thromres.2010.07.004.","journal-title":"Thromb Res"},{"issue":"2\u20133","key":"1985_CR32","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/s0304-4165(99)00087-2","volume":"1428","author":"CP Dietrich","year":"1999","unstructured":"Dietrich CP, Paiva JF, Castro RA, Chavante SF, Jeske W, Fareed J, Gorin PA, Mendes A, Nader HB. Structural features and anticoagulant activities of a novel natural low molecular weight heparin from the shrimp Penaeus brasiliensis. Biochem Biophys Acta. 1999;1428(2\u20133):273\u201383. https:\/\/doi.org\/10.1016\/s0304-4165(99)00087-2.","journal-title":"Biochem Biophys Acta"},{"issue":"12","key":"1985_CR33","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1093\/glycob\/cwh128","volume":"14","author":"M Cesaretti","year":"2004","unstructured":"Cesaretti M, Luppi E, Maccari F, Volpi N. Isolation and characterization of a heparin with high anticoagulant activity from the clam Tapes phylippinarum: evidence for the presence of a high content of antithrombin III binding site. Glycobiology. 2004;14(12):1275\u201384. https:\/\/doi.org\/10.1093\/glycob\/cwh128.","journal-title":"Glycobiology"},{"issue":"5","key":"1985_CR34","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/jps.23501","volume":"102","author":"L Fu","year":"2013","unstructured":"Fu L, Li G, Yang B, Onishi A, Li L, Sun P, Zhang F, Linhardt RJ. Structural characterization of pharmaceutical heparins prepared from different animal tissues. J Pharm Sci. 2013;102(5):1447\u201357. https:\/\/doi.org\/10.1002\/jps.23501.","journal-title":"J Pharm Sci"},{"issue":"2","key":"1985_CR35","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.carbpol.2011.05.015","volume":"86","author":"R Saravanan","year":"2011","unstructured":"Saravanan R, Shanmugam A. Is isolation and characterization of heparan sulfate from marine scallop Amussium pleuronectus (Linne.) an alternative source of heparin? Carbohydr Polymers. 2011;86(2):1082\u20134. https:\/\/doi.org\/10.1016\/j.carbpol.2011.05.015.","journal-title":"Carbohydr Polymers"},{"key":"1985_CR36","doi-asserted-by":"publisher","first-page":"173778","DOI":"10.1016\/j.ejphar.2020.173778","volume":"892","author":"U Ejaz","year":"2021","unstructured":"Ejaz U, Akhtar F, Xue J, Wan X, Zhang T, He S. Inhibitory potential of low molecular weight Heparin in cell adhesion; emphasis on tumor metastasis. Eur J Pharmacol. 2021;892:173778.","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"1985_CR37","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.thromres.2007.06.015","volume":"121","author":"M Marchetti","year":"2008","unstructured":"Marchetti M, Vignoli A, Russo L, Balducci D, Pagnoncelli M, Barbui T, Falanga A. Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin. Thromb Res. 2008;121(5):637\u201345.","journal-title":"Thromb Res"},{"issue":"1","key":"1985_CR38","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1080\/19336918.2020.1767489","volume":"14","author":"S-N Ma","year":"2020","unstructured":"Ma S-N, Mao Z-X, Wu Y, Liang M-X, Wang D-D, Chen X, Chang P-a, Zhang W, Tang J-H. The anti-cancer properties of heparin and its derivatives: a review and prospect. Cell Adh Migr. 2020;14(1):118\u201328.","journal-title":"Cell Adh Migr"},{"issue":"3","key":"1985_CR39","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1046\/j.1365-2613.2000.00150.x","volume":"81","author":"K Norrby","year":"2000","unstructured":"Norrby K. 2.5 kDa and 5.0 kDa heparin fragments specifically inhibit microvessel sprouting and network formation in VEGF165-mediated mammalian angiogenesis. Int J Exp Pathol. 2000;81(3):191\u20138.","journal-title":"Int J Exp Pathol"},{"issue":"11","key":"1985_CR40","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1161\/01.ATV.0000090671.56682.D7","volume":"23","author":"AA Khorana","year":"2003","unstructured":"Khorana AA, Sahni A, Altland OD, Francis CW. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler Thromb Vasc Biol. 2003;23(11):2110\u20135.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"1985_CR41","first-page":"815","volume":"16","author":"G-F von Tempelhoff","year":"2000","unstructured":"von Tempelhoff G-F, Harenberg J, Niemann F, Hommel G, Kirkpatrick CJ, Heilmann L. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int J Oncol. 2000;16(4):815\u201339.","journal-title":"Int J Oncol"},{"issue":"5","key":"1985_CR42","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s10585-012-9461-9","volume":"29","author":"T Sudha","year":"2012","unstructured":"Sudha T, Phillips P, Kanaan C, Linhardt RJ, Borsig L, Mousa SA. Inhibitory effect of non-anticoagulant heparin (S-NACH) on pancreatic cancer cell adhesion and metastasis in human umbilical cord vessel segment and in mouse model. Clin Exp Metastasis. 2012;29(5):431\u20139. https:\/\/doi.org\/10.1007\/s10585-012-9461-9.","journal-title":"Clin Exp Metastasis"},{"issue":"9","key":"1985_CR43","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1007\/s00277-018-3343-4","volume":"97","author":"A Vignoli","year":"2018","unstructured":"Vignoli A, Marchetti M, Falanga A. Acute promyelocytic leukemia cell adhesion to vascular endothelium is reduced by heparins. Ann Hematol. 2018;97(9):1555\u201362.","journal-title":"Ann Hematol"},{"issue":"5","key":"1985_CR44","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1177\/1076029617729215","volume":"24","author":"EP Dimakakos","year":"2018","unstructured":"Dimakakos EP, Vathiotis I, Syrigos K. The role of tinzaparin in oncology. Clin Appl Thromb Hemost. 2018;24(5):697\u2013707.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"4","key":"1985_CR45","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3892\/etm.2014.1911","volume":"8","author":"W Yin","year":"2014","unstructured":"Yin W, Zhang J, Jiang Y, Juan S. Combination therapy with low molecular weight heparin and adriamycin results in decreased breast cancer cell metastasis in C3H mice. Exp Ther Med. 2014;8(4):1213\u20138.","journal-title":"Exp Ther Med"},{"issue":"24","key":"1985_CR46","doi-asserted-by":"publisher","first-page":"6543","DOI":"10.1016\/j.biomaterials.2014.04.050","volume":"35","author":"F Alam","year":"2014","unstructured":"Alam F, Al-Hilal TA, Chung SW, Seo D, Mahmud F, Kim HS, Kim SY, Byun Y. Oral delivery of a potent anti-angiogenic heparin conjugate by chemical conjugation and physical complexation using deoxycholic acid. Biomaterials. 2014;35(24):6543\u201352. https:\/\/doi.org\/10.1016\/j.biomaterials.2014.04.050.","journal-title":"Biomaterials"},{"issue":"3","key":"1985_CR47","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.3892\/ijo.2014.2803","volume":"46","author":"R Alyahya","year":"2015","unstructured":"Alyahya R, Sudha T, Racz M, Stain SC, Mousa SA. Anti-metastasis efficacy and safety of non-anticoagulant heparin derivative versus low molecular weight heparin in surgical pancreatic cancer models. Int J Oncol. 2015;46(3):1225\u201331.","journal-title":"Int J Oncol"},{"issue":"2","key":"1985_CR48","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1139\/bcb-2018-0246","volume":"98","author":"SC Lin","year":"2020","unstructured":"Lin SC, Wu CP, Tseng T, Jhang Y, Lee SC. Role of syndecan-1 and exogenous heparin in hepatoma sphere formation. Biochem Cell Biol. 2020;98(2):112\u20139. https:\/\/doi.org\/10.1139\/bcb-2018-0246.","journal-title":"Biochem Cell Biol"},{"issue":"24","key":"1985_CR49","doi-asserted-by":"publisher","first-page":"6543","DOI":"10.1016\/j.biomaterials.2014.04.050","volume":"35","author":"F Alam","year":"2014","unstructured":"Alam F, Al-Hilal TA, Chung SW, Seo D, Mahmud F, Kim HS, Kim SY, Byun Y. Oral delivery of a potent anti-angiogenic heparin conjugate by chemical conjugation and physical complexation using deoxycholic acid. Biomaterials. 2014;35(24):6543\u201352.","journal-title":"Biomaterials"},{"key":"1985_CR50","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jconrel.2014.12.015","volume":"199","author":"J-y Kim","year":"2015","unstructured":"Kim J-y, Al-Hilal TA, Chung SW, Kim SY, Ryu GH, Son WC, Byun Y. Antiangiogenic and anticancer effect of an orally active low molecular weight heparin conjugates and its application to lung cancer chemoprevention. J Control Release. 2015;199:122\u201331.","journal-title":"J Control Release"},{"issue":"11","key":"1985_CR51","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1021\/acs.molpharmaceut.5b00348","volume":"12","author":"J Park","year":"2015","unstructured":"Park J, Kim J-y, Hwang SR, Mahmud F, Byun Y. Chemical conjugate of low molecular weight heparin and suramin fragment inhibits tumor growth possibly by blocking VEGF165. Mol Pharm. 2015;12(11):3935\u201342.","journal-title":"Mol Pharm"},{"issue":"3","key":"1985_CR52","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2147\/vhrm.2006.2.3.213","volume":"2","author":"N Nishida","year":"2006","unstructured":"Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in cancer. Vasc Health Risk Manag. 2006;2(3):213\u20139. https:\/\/doi.org\/10.2147\/vhrm.2006.2.3.213.","journal-title":"Vasc Health Risk Manag"},{"issue":"3","key":"1985_CR53","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/wdev.176","volume":"4","author":"DM Ornitz","year":"2015","unstructured":"Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015;4(3):215\u201366. https:\/\/doi.org\/10.1002\/wdev.176.","journal-title":"Wiley Interdiscip Rev Dev Biol"},{"issue":"5","key":"1985_CR54","doi-asserted-by":"publisher","first-page":"639","DOI":"10.2174\/156800909789057006","volume":"9","author":"M Korc","year":"2009","unstructured":"Korc M, Friesel RE. The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets. 2009;9(5):639\u201351. https:\/\/doi.org\/10.2174\/156800909789057006.","journal-title":"Curr Cancer Drug Targets"},{"key":"1985_CR55","doi-asserted-by":"publisher","first-page":"100192","DOI":"10.1016\/j.ctarc.2020.100192","volume":"24","author":"J Atallah","year":"2020","unstructured":"Atallah J, Khachfe HH, Berro J, Assi HI. The use of heparin and heparin-like molecules in cancer treatment: a review. Cancer Treat Res Commun. 2020;24:100192. https:\/\/doi.org\/10.1016\/j.ctarc.2020.100192.","journal-title":"Cancer Treat Res Commun"},{"key":"1985_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/fft2.466","author":"T Azevedo","year":"2024","unstructured":"Azevedo T, Ferreira T, Pe\u00f1a-Corona SI, Cortes H, Silva-Reis R, da Costa RMG, Faustino-Rocha AI, Oliveira PA, Calina D, Cardoso SM, B\u00fcsselberg D, Leyva-G\u00f3mez G, Sharifi-Rad J, Cho WC. Natural products-based antiangiogenic agents: new frontiers in cancer therapy. Food Front. 2024. https:\/\/doi.org\/10.1002\/fft2.466.","journal-title":"Food Front"},{"issue":"1","key":"1985_CR57","first-page":"3","volume":"110","author":"Y Uzun","year":"2009","unstructured":"Uzun Y, Akdogan E, Ozdemir F, Ovali E. The effects of heparin on DLD-1 colon cancer cell line. Bratisl Lek Listy. 2009;110(1):3\u20136.","journal-title":"Bratisl Lek Listy"},{"issue":"21","key":"1985_CR58","first-page":"6196","volume":"60","author":"A Collen","year":"2000","unstructured":"Collen A, Smorenburg SM, Peters E, Lupu F, Koolwijk P, Van Noorden C, van Hinsbergh VW. Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Res. 2000;60(21):6196\u2013200.","journal-title":"Cancer Res"},{"issue":"1","key":"1985_CR59","doi-asserted-by":"publisher","first-page":"14","DOI":"10.14302\/issn.2639-1716.jn-17-1499","volume":"1","author":"WA Arab","year":"2017","unstructured":"Arab WA, Kotb R, Sirois M, Rousseau \u00c9. The role of heparin in lung cancer. J Neoplasms. 2017;1(1):14.","journal-title":"J Neoplasms"},{"issue":"6","key":"1985_CR60","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/mbc.0000000000000611","volume":"28","author":"GMT Chang","year":"2017","unstructured":"Chang GMT, Atkinson HM, Berry LR, Chan AKC. Inhibition of plasmin generation in plasma by heparin, low molecular weight heparin, and a covalent antithrombin-heparin complex. Blood Coagul Fibrinolysis. 2017;28(6):431\u20137. https:\/\/doi.org\/10.1097\/mbc.0000000000000611.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"29","key":"1985_CR61","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1200\/jco.2009.22.4584","volume":"27","author":"NM Kuderer","year":"2009","unstructured":"Kuderer NM, Ortel TL, Francis CW. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol. 2009;27(29):4902\u201311. https:\/\/doi.org\/10.1200\/jco.2009.22.4584.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1985_CR62","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1160\/TH06-01-0057","volume":"96","author":"X Jiang","year":"2006","unstructured":"Jiang X, Guo YL, Bromberg ME. Formation of tissue factor-factor VIIa-factor Xa complex prevents apoptosis in human breast cancer cells. Thromb Haemost. 2006;96(2):196\u2013201.","journal-title":"Thromb Haemost"},{"issue":"1","key":"1985_CR63","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1055\/s-2002-20564","volume":"28","author":"NM Varki","year":"2002","unstructured":"Varki NM, Varki A. Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. Semin Thromb Hemost. 2002;28(1):53\u201366. https:\/\/doi.org\/10.1055\/s-2002-20564.","journal-title":"Semin Thromb Hemost"},{"issue":"09","key":"1985_CR64","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1160\/TH04-02-0069","volume":"92","author":"SA Mousa","year":"2004","unstructured":"Mousa SA, Mohamed S. Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. Thromb Haemost. 2004;92(09):627\u201333.","journal-title":"Thromb Haemost"},{"key":"1985_CR65","first-page":"643","volume":"07","author":"A Amirkhosravi","year":"2007","unstructured":"Amirkhosravi A, Meyer T, Amaya M, Davila M, Mousa SA, Robson T, Francis JL. The role of tissue factor pathway inhibitor in tumor growth and metastasis. Semin Thromb Hemost. 2007;07:643\u201352.","journal-title":"Semin Thromb Hemost"},{"key":"1985_CR66","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1055\/s-2007-991532","volume":"07","author":"E Sierko","year":"2007","unstructured":"Sierko E, Wojtukiewicz MZ, Kisiel W. The role of tissue factor pathway inhibitor-2 in cancer biology. Semin Thromb Hemost. 2007;07:653\u20139.","journal-title":"Semin Thromb Hemost"},{"key":"1985_CR67","first-page":"49","volume-title":"Anticoagulants, antiplatelets, and thrombolytics","author":"SA Mousa","year":"2004","unstructured":"Mousa SA. Are low molecular weight heparins the same? In: Mousa SA, editor. Anticoagulants, antiplatelets, and thrombolytics. New Jersey: Humana Press; 2004. p. 49\u201359."},{"issue":"Pt 11","key":"1985_CR68","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1242\/jcs.107.11.3201","volume":"107","author":"N Quarto","year":"1994","unstructured":"Quarto N, Amalric F. Heparan sulfate proteoglycans as transducers of FGF-2 signalling. J Cell Sci. 1994;107(Pt 11):3201\u201312. https:\/\/doi.org\/10.1242\/jcs.107.11.3201.","journal-title":"J Cell Sci"},{"key":"1985_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22137053","author":"P Sarantis","year":"2021","unstructured":"Sarantis P, Bokas A, Papadimitropoulou A, Koustas E, Theocharis S, Papakotoulas P, Schizas D, Papalampros A, Felekouras E, Papavassiliou AG, Karamouzis MV. Combinatorial treatment of tinzaparin and chemotherapy can induce a significant antitumor effect in pancreatic cancer. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22137053.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1985_CR70","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/1097-0142","volume":"74","author":"B Lebeau","year":"1994","unstructured":"Lebeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delaisements C, Mornet M, Brun J, Hurdebourcq JP, Lemarie E. Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer. 1994;74(1):38\u201345. https:\/\/doi.org\/10.1002\/1097-0142.","journal-title":"Cancer"},{"issue":"1","key":"1985_CR71","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/sj.bjc.6601897","volume":"91","author":"PH Jones","year":"2004","unstructured":"Jones PH, Christodoulos K, Dobbs N, Thavasu P, Balkwill F, Blann AD, Caine GJ, Kumar S, Kakkar AJ, Gompertz N, Talbot DC, Ganesan TS, Harris AL. Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer. Br J Cancer. 2004;91(1):30\u20136. https:\/\/doi.org\/10.1038\/sj.bjc.6601897.","journal-title":"Br J Cancer"},{"issue":"1","key":"1985_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-14-204","volume":"14","author":"U Pelzer","year":"2014","unstructured":"Pelzer U, Hilbig A, Stieler JM, Bahra M, Sinn M, Gebauer B, D\u00f6rken B, Riess H. Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer\u2013the CONKO 004 pilot trial. BMC Cancer. 2014;14(1):1\u20136.","journal-title":"BMC Cancer"},{"issue":"5","key":"1985_CR73","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/jco.2015.64.0268","volume":"34","author":"F Macbeth","year":"2016","unstructured":"Macbeth F, Noble S, Evans J, Ahmed S, Cohen D, Hood K, Knoyle D, Linnane S, Longo M, Moore B, Woll PJ, Appel W, Dickson J, Ferry D, Brammer C, Griffiths G. Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial. J Clin Oncol. 2016;34(5):488\u201394. https:\/\/doi.org\/10.1200\/jco.2015.64.0268.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1985_CR74","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41416-019-0533-3","volume":"121","author":"HJ Groen","year":"2019","unstructured":"Groen HJ, van der Heijden EH, Klinkenberg TJ, Biesma B, Aerts J, Verhagen A, Kloosterziel C, Pieterman R, van den Borne B, Smit HJ. Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study. Br J Cancer. 2019;121(5):372\u20137.","journal-title":"Br J Cancer"},{"issue":"5","key":"1985_CR75","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/JCO.2015.64.0268","volume":"34","author":"F Macbeth","year":"2016","unstructured":"Macbeth F, Noble S, Evans J, Ahmed S, Cohen D, Hood K, Knoyle D, Linnane S, Longo M, Moore B. Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial. J Clin Oncol. 2016;34(5):488\u201394.","journal-title":"J Clin Oncol"},{"key":"1985_CR76","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01220-2018","author":"G Meyer","year":"2018","unstructured":"Meyer G, Besse B, Doubre H, Charles-Nelson A, Aquilanti S, Izadifar A, Azarian R, Monnet I, Lamour C, Descourt R. Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial. Eur Respir J. 2018. https:\/\/doi.org\/10.1183\/13993003.01220-2018.","journal-title":"Eur Respir J"},{"key":"1985_CR77","doi-asserted-by":"publisher","first-page":"120779","DOI":"10.1016\/j.carbpol.2023.120779","volume":"311","author":"Y Song","year":"2023","unstructured":"Song Y, Kouta A, Cera LM, Xia K, Zhang F, Kraemer R, Fareed J, Linhardt RJ, Jeske W. Absolute pharmacokinetics of heparin in primates. Carbohydr Polym. 2023;311:120779. https:\/\/doi.org\/10.1016\/j.carbpol.2023.120779.","journal-title":"Carbohydr Polym"},{"issue":"2","key":"1985_CR78","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"AY Lee","year":"2003","unstructured":"Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146\u201353. https:\/\/doi.org\/10.1056\/NEJMoa025313.","journal-title":"N Engl J Med"},{"issue":"10","key":"1985_CR79","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.3324\/haematol.2017.182865","volume":"103","author":"M Galli","year":"2018","unstructured":"Galli M, Chatterjee M, Grasso M, Specchia G, Magen H, Einsele H, Celeghini I, Barbieri P, Paoletti D, Pace S, Sanderson RD, Rambaldi A, Nagler A. Phase I study of the heparanase inhibitor roneparstat: an innovative approach for ultiple myeloma therapy. Haematologica. 2018;103(10):e469\u201372. https:\/\/doi.org\/10.3324\/haematol.2017.182865.","journal-title":"Haematologica"},{"key":"1985_CR80","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.3389\/fonc.2019.01316","volume":"9","author":"DR Coombe","year":"2019","unstructured":"Coombe DR, Gandhi NS. Heparanase: a challenging cancer drug target. Front Oncol. 2019;9:1316. https:\/\/doi.org\/10.3389\/fonc.2019.01316.","journal-title":"Front Oncol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-01985-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-01985-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-01985-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T12:55:13Z","timestamp":1740401713000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-01985-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1985"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-01985-7","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,24]]},"assertion":[{"value":"7 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"231"}}